ZOLEDRONATE SUPPRESSES BONE TURNOVER FOR AT LEAST 2 YEARS: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL

被引：0
|
作者：
Grey, A. [1 ]
Bolland, M. [1 ]
Horne, A. [1 ]
Gamble, G. [1 ]
Reid, I. R. [1 ]
机构：
[1] Univ Auckland, Auckland 1, New Zealand
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [1] The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
    Grey, Andrew
    Bolland, Mark J.
    Wattie, Diana
    Horne, Anne
    Gamble, Greg
    Reid, Ian R.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02): : 538 - 544
  • [2] Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial
    Verheyen, Nicolas
    Gruebler, Martin R.
    Meinitzer, Andreas
    Trummer, Christian
    Schwetz, Verena
    Amrein, Karin
    Dimai, Hans P.
    Maerz, Winfried
    Catena, Cristiana
    von Lewinski, Dirk
    Voelkl, Jakob
    Alesutan, Ioana
    Fahrleitner-Pammer, Astrid
    Brussee, Helmut
    Pilz, Stefan
    Tomaschitz, Andreas
    [J]. BONE, 2017, 105 : 212 - 217
  • [3] Soymilk or progesterone for prevention of bone loss - A 2 year randomized, placebo-controlled trial
    Lydeking-Olsen, E
    Beck-Jensen, JE
    Setchell, KDR
    Holm-Jensen, T
    [J]. EUROPEAN JOURNAL OF NUTRITION, 2004, 43 (04) : 246 - 257
  • [4] Placebo-Controlled Feasibility Randomized Trial?
    Sanz Rubiales, Alvaro
    Luisa del Valle, Maria
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2014, 48 (01) : E4 - E5
  • [5] Randomized, placebo-controlled trial - Reply
    Kamyabi, Z
    [J]. ANNALS OF SAUDI MEDICINE, 2004, 24 (02) : 145 - 145
  • [6] The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women EDITORIAL COMMENT
    Grey, Andrew
    Bolland, Mark J.
    Wattie, Diana
    Horne, Anne
    Gamble, Greg
    Reid, Ian R.
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2009, 64 (07) : 462 - 463
  • [7] Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial
    Dalbeth, Nicola
    Aati, Opetaia
    Gamble, Gregory D.
    Horne, Anne
    House, Meaghan E.
    Roger, Mark
    Doyle, Anthony J.
    Chhana, Ashika
    McQueen, Fiona M.
    Reid, Ian R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (06) : 1044 - 1051
  • [8] Effect of flavanols on bone turnover markers in individuals with type 2 diabetes - a 3-month randomized placebo-controlled FLAVA trial
    Waqas, Komal
    Rashid, Mardin
    van der Eerder, Bram. J. C.
    Berk, Kirsten
    Zillikens, M. Carola
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 145 - 145
  • [9] A randomized placebo-controlled trial of mebendazole for halitosis
    Ermis, B
    Aslan, T
    Beder, L
    Unalacak, M
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2002, 156 (10): : 995 - 998
  • [10] Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial
    Grey, Andrew
    Bolland, Mark
    Mihov, Bobby
    Wong, Sumwai
    Horne, Anne
    Gamble, Greg
    Reid, Ian R.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (01) : 166 - 172
12345